Literature DB >> 9894650

Effect of a single element subcutaneous array electrode added to a transvenous electrode configuration on the defibrillation field and the defibrillation threshold.

V Kühlkamp1, V Dörnberger, K Khalighi, C Mewis, R Suchalla, G Ziemer, L Seipel.   

Abstract

Even with the use of biphasic shocks, up to 5% of patients need an additional subcutaneous lead to obtain a defibrillation safety margin of at least 10 J. The number of patients requiring additional subcutaneous leads may even increase, because recent generation devices have a < 34 J maximum output in order to decrease their size. In 20 consecutive patients, a single element subcutaneous array lead was implanted in addition to a transvenous lead system consisting of a right ventricular (RV) and a vena cava superior lead using a single infraclavicular incision. The RV lead acted as the cathode; the subcutaneous lead and the lead in the subclavian vein acted as the anode. The biphasic defibrillation threshold was determined using a binary search protocol. Patients were randomized as to whether to start them with the transvenous lead configuration or the combination of the transvenous lead and the subcutaneous lead. In addition, a simplified assessment of the defibrillation field was performed by determining the interelectrode area for the transvenous lead only and the transvenous lead in combination with the subcutaneous lead from a biplane chest X ray. The intraoperative defibrillation threshold was reconfirmed after 1 week, after 3 months, and after 12 months. The mean defibrillation threshold with the additional subcutaneous lead was significantly (P = 0.0001) lower (5.7 +/- 2.9 J) than for the transvenous lead system (9.5 +/- 4.6 J). With the subcutaneous lead, the impedance of the high voltage circuit decreased from 48.9 +/- 7.4 omega to 39.2 +/- 5.0 omega. In the frontal plane, the interelectrode area increased by 11.3% +/- 5.5% (P < 0.0001) and in the lateral plane by 29.5% +/- 12.4% (P < 0.0001). The defibrillation threshold did not increase during follow-up. Complications with the subcutaneous electrode were not observed during a follow-up of 15.8 +/- 2 months. The single finger array lead is useful in order to lower the defibrillation threshold and can be used in order to lower the defibrillation threshold.

Entities:  

Mesh:

Year:  1998        PMID: 9894650     DOI: 10.1111/j.1540-8159.1998.tb00036.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  5 in total

1.  [Is intraoperative ICD-testing still necessary?].

Authors:  C Mewis; H-R Neuberger; A Buob
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-06

2.  Incidence and clinical predictors of low defibrillation safety margin at time of implantable defibrillator implantation.

Authors:  Zhongwei Cheng; Mintu Turakhia; Ronald Lo; Anurag Gupta; Paul C Zei; Henry H Hsia; Amin Al-Ahmad; Paul J Wang
Journal:  J Interv Card Electrophysiol       Date:  2012-03-06       Impact factor: 1.900

3.  Incidence of very high defibrillation thresholds (DFT) and efficacy of subcutaneous (SQ) array insertion during implantable cardioverter defibrillator (ICD) implantation.

Authors:  Atul Verma; Alexander J Kaplan; Bradley Sarak; Richard Oosthuizen; Marianne Beardsall; Jan Higgenbottam; Zaev Wulffhart; Yaariv Khaykin
Journal:  J Interv Card Electrophysiol       Date:  2010-09-24       Impact factor: 1.900

4.  Implantation of additional subcutaneous array electrode reduces defibrillation threshold in ICD patients - preliminary results.

Authors:  Maciej Kempa; Szymon Budrejko; Lukasz Drelich; Tomasz Królak; Grzegorz Raczak; Dariusz Kozłowski
Journal:  Arch Med Sci       Date:  2013-06-21       Impact factor: 3.318

5.  Incidence of ineffective safety margin testing (<10 J) and efficacy of routine subcutaneous array insertion during implantable cardioverter defibrillator implantation.

Authors:  Marc-Alexander Ohlow; Marcus Roos; Bernward Lauer; J Christoph Geller
Journal:  Indian Pacing Electrophysiol J       Date:  2016-02-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.